1. Home
  2. CHCT vs TRDA Comparison

CHCT vs TRDA Comparison

Compare CHCT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Community Healthcare Trust Incorporated

CHCT

Community Healthcare Trust Incorporated

N/A

Current Price

$16.63

Market Cap

493.1M

Sector

Real Estate

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$12.73

Market Cap

481.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHCT
TRDA
Founded
2014
2016
Country
United States
United States
Employees
N/A
183
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.1M
481.6M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
CHCT
TRDA
Price
$16.63
$12.73
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$18.33
$20.00
AVG Volume (30 Days)
356.3K
191.6K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
11.46%
N/A
EPS Growth
134.78
N/A
EPS
0.08
N/A
Revenue
$121,195,000.00
$25,421,000.00
Revenue This Year
$9.06
$51.37
Revenue Next Year
$8.61
$46.98
P/E Ratio
$208.38
N/A
Revenue Growth
4.67
N/A
52 Week Low
$13.23
$4.93
52 Week High
$18.90
$12.93

Technical Indicators

Market Signals
Indicator
CHCT
TRDA
Relative Strength Index (RSI) 42.34 59.95
Support Level $16.18 $9.59
Resistance Level $17.34 N/A
Average True Range (ATR) 0.52 0.86
MACD -0.08 0.09
Stochastic Oscillator 27.37 84.15

Price Performance

Historical Comparison
CHCT
TRDA

About CHCT Community Healthcare Trust Incorporated

Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: